Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07341-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Xin Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Predisposition to Disease, Germ-Line Mutation, Tumor Suppressor Protein p53. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical Board Open Competition Grants, CAMS Innovation Fund for Medical Sciences, the National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Purpose
In the present study, we addressed the inconsistency between the testing criteria and diverse phenotypes for germline TP53 mutation in patients with breast cancer in the Chinese population.
Method
We proposed a new added item (synchronous or metachronous bilateral breast cancer) as one of the testing criteria (aimed at high-penetrance breast cancer susceptibility genes) and applied it for determining TP53 germline mutation status in 420 female patients with breast cancer using multigene panel-based next-generation sequencing, Sanger sequencing, and mass spectrometry.
Results
We found that 1.4% of patients carried a pathogenic or likely pathogenic germline TP53 mutation. Compared with BRCA mutation carriers (8.0%) and non-carriers (7.1%), TP53 mutation carriers (33.3%) developed breast cancer earlier. The majority of TP53 mutation carriers (66.7%) developed breast cancer after age 30 and had bilateral breast cancer (33.3%). Pedigree investigation of four TP53 carriers and a patient with a TP53 variant of unknown significance revealed that neither of their parents harbored the same mutations as the probands, indicating that the mutations might occur de novo.
Conclusion
Our study revealed distinguishing features of TP53 carriers among Chinese women with breast cancer, which is inconsistent with the currently used testing criteria; therefore, the newly proposed testing criteria may be more appropriate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
- Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China. zhouydpumch@126.com.
Förderung
- China Medical Board Open Competition Grants
- CAMS Innovation Fund for Medical Sciences
- the National High Level Hospital Clinical Research Funding
Zitieren
APA
Huang, X., Chen, C., Lin, Y., Wang, C., Zhou, X., Xu, Y., Sun, Q., & Zhou, Y. (2024). Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07341-7
Vancouver
Huang X, Chen C, Lin Y, Wang C, Zhou X, Xu Y, et al. Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07341-7
BibTeX
@article{Huang2024,
author = {Huang, Xin and Chen, Chang and Lin, Yan and Wang, Changjun and Zhou, Xingtong and Xu, Ying and Sun, Qiang and Zhou, Yidong},
title = {Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07341-7}
}
EUVIMED